JP2019534706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534706A5 JP2019534706A5 JP2019520386A JP2019520386A JP2019534706A5 JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5 JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- seq
- heavy chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 21
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102200033974 rs1555427497 Human genes 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021190070A JP7383682B2 (ja) | 2016-10-17 | 2021-11-24 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2023191037A JP2023184697A (ja) | 2016-10-17 | 2023-11-08 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2025146227A JP2025175010A (ja) | 2016-10-17 | 2025-09-03 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409081P | 2016-10-17 | 2016-10-17 | |
| US62/409,081 | 2016-10-17 | ||
| PCT/IB2017/056093 WO2018073680A1 (en) | 2016-10-17 | 2017-10-03 | Anti-edb antibodies and antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190070A Division JP7383682B2 (ja) | 2016-10-17 | 2021-11-24 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534706A JP2019534706A (ja) | 2019-12-05 |
| JP2019534706A5 true JP2019534706A5 (enExample) | 2020-11-12 |
| JP7039577B2 JP7039577B2 (ja) | 2022-03-22 |
Family
ID=60117722
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520386A Active JP7039577B2 (ja) | 2016-10-17 | 2017-10-03 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2021190070A Active JP7383682B2 (ja) | 2016-10-17 | 2021-11-24 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2023191037A Pending JP2023184697A (ja) | 2016-10-17 | 2023-11-08 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2025146227A Pending JP2025175010A (ja) | 2016-10-17 | 2025-09-03 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190070A Active JP7383682B2 (ja) | 2016-10-17 | 2021-11-24 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2023191037A Pending JP2023184697A (ja) | 2016-10-17 | 2023-11-08 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
| JP2025146227A Pending JP2025175010A (ja) | 2016-10-17 | 2025-09-03 | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US20190269791A1 (enExample) |
| EP (3) | EP3525828B1 (enExample) |
| JP (4) | JP7039577B2 (enExample) |
| KR (1) | KR102338660B1 (enExample) |
| CN (2) | CN110087691B (enExample) |
| AU (3) | AU2017344440B2 (enExample) |
| CA (1) | CA3040423A1 (enExample) |
| DK (1) | DK3525828T3 (enExample) |
| ES (1) | ES3007557T3 (enExample) |
| FI (1) | FI3525828T3 (enExample) |
| HR (1) | HRP20250056T1 (enExample) |
| HU (1) | HUE070615T2 (enExample) |
| IL (2) | IL266112B2 (enExample) |
| LT (1) | LT3525828T (enExample) |
| MX (2) | MX2019004434A (enExample) |
| PL (1) | PL3525828T3 (enExample) |
| PT (1) | PT3525828T (enExample) |
| RS (1) | RS66524B1 (enExample) |
| RU (1) | RU2758632C2 (enExample) |
| SG (1) | SG11201903400WA (enExample) |
| SI (1) | SI3525828T1 (enExample) |
| WO (1) | WO2018073680A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR20210102334A (ko) * | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| KR102614063B1 (ko) | 2020-12-24 | 2023-12-19 | 대화제약 주식회사 | 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체 |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| JP2025511872A (ja) | 2022-04-08 | 2025-04-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多部位受容体及びシグナル伝達複合体 |
| WO2025011561A1 (en) * | 2023-07-10 | 2025-01-16 | Wuxi Xdc (Shanghai) Co., Ltd. | Antibody-drug conjugates and production thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| WO1997026885A1 (en) | 1996-01-23 | 1997-07-31 | The General Hospital Corporation Doing Business As Massachusetts General Hospital | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| EP1719528B1 (en) * | 2000-02-24 | 2011-09-28 | Philogen S.p.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| AU2001242432B2 (en) | 2000-02-24 | 2007-11-08 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| WO2002100326A2 (en) | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| EP1461360B1 (en) * | 2002-01-03 | 2010-08-18 | Bayer Schering Pharma Aktiengesellschaft | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
| ATE452912T1 (de) | 2002-03-11 | 2010-01-15 | Philogen Spa | Antikörper aus anti-ed-b l19 gerichtet auf tumorblutgefässe |
| NZ537870A (en) * | 2002-07-31 | 2007-03-30 | Schering Ag | New effector conjugates, process for their production and their pharmaceutical use |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| DE602006012667D1 (de) * | 2005-05-11 | 2010-04-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
| JP5748392B2 (ja) | 2005-10-05 | 2015-07-15 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 絹タンパク質 |
| EP1842553A1 (en) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| WO2007128557A1 (en) * | 2006-05-03 | 2007-11-15 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| EA036322B1 (ru) | 2007-04-02 | 2020-10-26 | Филоджен С.П.А. | Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов |
| CN101754978B (zh) | 2007-07-25 | 2013-06-05 | 菲洛根股份公司 | 一种与肺癌和淋巴瘤相关的抗原 |
| ES2382058T3 (es) * | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos |
| CA2948693C (en) * | 2009-02-13 | 2018-09-04 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| ES2640981T3 (es) | 2009-08-05 | 2017-11-07 | Philogen S.P.A. | Selección como diana de neovasculatura de médula ósea |
| AR077879A1 (es) | 2009-08-17 | 2011-09-28 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| AU2011307236A1 (en) | 2010-09-29 | 2013-03-28 | Philogen S.P.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
| EP2635310A2 (en) | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| HUE053589T2 (hu) | 2011-11-17 | 2021-07-28 | Pfizer | Citotoxikus peptidek és azok antitest-hatóanyag konjugátumai |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| WO2014124316A2 (en) * | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| WO2014174105A1 (en) * | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| JP6236540B2 (ja) | 2014-01-27 | 2017-11-22 | ファイザー・インク | 二官能性細胞毒性剤 |
| GB2538023A (en) * | 2014-02-03 | 2016-11-02 | Philochem Ag | Targeted drug conjugates |
| KR102430829B1 (ko) * | 2014-04-25 | 2022-08-09 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| TWI812873B (zh) | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| CA2949032A1 (en) | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Site specific her2 antibody drug conjugates |
-
2017
- 2017-10-03 KR KR1020197013908A patent/KR102338660B1/ko active Active
- 2017-10-03 ES ES17784700T patent/ES3007557T3/es active Active
- 2017-10-03 CN CN201780078019.XA patent/CN110087691B/zh active Active
- 2017-10-03 RU RU2019111303A patent/RU2758632C2/ru active
- 2017-10-03 PT PT177847001T patent/PT3525828T/pt unknown
- 2017-10-03 WO PCT/IB2017/056093 patent/WO2018073680A1/en not_active Ceased
- 2017-10-03 HU HUE17784700A patent/HUE070615T2/hu unknown
- 2017-10-03 JP JP2019520386A patent/JP7039577B2/ja active Active
- 2017-10-03 SI SI201731585T patent/SI3525828T1/sl unknown
- 2017-10-03 EP EP17784700.1A patent/EP3525828B1/en active Active
- 2017-10-03 EP EP25168356.1A patent/EP4635516A2/en active Pending
- 2017-10-03 EP EP24223209.8A patent/EP4617283A2/en active Pending
- 2017-10-03 MX MX2019004434A patent/MX2019004434A/es unknown
- 2017-10-03 IL IL266112A patent/IL266112B2/en unknown
- 2017-10-03 IL IL310865A patent/IL310865A/en unknown
- 2017-10-03 SG SG11201903400WA patent/SG11201903400WA/en unknown
- 2017-10-03 HR HRP20250056TT patent/HRP20250056T1/hr unknown
- 2017-10-03 CN CN202310030234.XA patent/CN116251196A/zh active Pending
- 2017-10-03 LT LTEPPCT/IB2017/056093T patent/LT3525828T/lt unknown
- 2017-10-03 AU AU2017344440A patent/AU2017344440B2/en active Active
- 2017-10-03 FI FIEP17784700.1T patent/FI3525828T3/fi active
- 2017-10-03 US US16/342,275 patent/US20190269791A1/en not_active Abandoned
- 2017-10-03 DK DK17784700.1T patent/DK3525828T3/da active
- 2017-10-03 RS RS20250049A patent/RS66524B1/sr unknown
- 2017-10-03 CA CA3040423A patent/CA3040423A1/en active Pending
- 2017-10-03 PL PL17784700.1T patent/PL3525828T3/pl unknown
-
2019
- 2019-04-15 MX MX2024003463A patent/MX2024003463A/es unknown
-
2020
- 2020-10-26 AU AU2020260375A patent/AU2020260375B2/en active Active
-
2021
- 2021-11-24 JP JP2021190070A patent/JP7383682B2/ja active Active
-
2023
- 2023-02-09 US US18/166,774 patent/US11833216B2/en active Active
- 2023-10-23 US US18/492,348 patent/US20240156977A1/en active Pending
- 2023-10-23 US US18/492,055 patent/US20240181071A1/en active Pending
- 2023-11-08 JP JP2023191037A patent/JP2023184697A/ja active Pending
- 2023-12-04 US US18/528,539 patent/US20240261423A1/en active Pending
-
2024
- 2024-02-23 AU AU2024201216A patent/AU2024201216A1/en active Pending
-
2025
- 2025-09-03 JP JP2025146227A patent/JP2025175010A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534706A5 (enExample) | ||
| US11833120B2 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
| CN110869393B (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| CN113423735B (zh) | 抗-紧密连接蛋白抗体及其用途 | |
| Richards | Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery | |
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| JP2021502810A5 (enExample) | ||
| WO2019170131A1 (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| JP2018509908A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| Potala et al. | Targeted therapy of cancer using diphtheria toxin-derived immunotoxins | |
| WO2012047724A4 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP2017535246A5 (enExample) | ||
| JP2016512832A5 (enExample) | ||
| JP2016518332A5 (enExample) | ||
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| JP2010535713A5 (enExample) | ||
| JP2014511348A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| Papageorgiou et al. | Monoclonal antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab | |
| FI3525828T3 (fi) | Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja | |
| JP2020504607A5 (enExample) | ||
| JP2008515889A5 (enExample) |